Deal Ends Today·Save 35% annual plan
GIP/GLP-1 receptor agonistReviewed for 2026 plan year

Does Blue Cross Blue Shield of Illinois Cover Mounjaro?

The verdict

Conditional on most plans

Blue Cross Blue Shield of Illinois (an HCSC plan) covers Mounjaro for type 2 diabetes with prior authorization across commercial, ACA, and Medicare Part D lines. BCBS of Illinois does not cover Mounjaro for weight loss. Illinois Medicaid covers Mounjaro for T2D but explicitly excludes weight-loss GLP-1s — a cleaner exclusion than many states. The weight-loss tirzepatide is Zepbound, with separate coverage.

MedicareConditional
CommercialConditional
See the difference

Coverage is set by your specific plan and formulary. This is a research summary — always confirm with Blue Cross Blue Shield of Illinois using your member ID.

Reviewed for 2026
Checked against the active plan year
Sourced from formularies
Blue Cross Blue Shield of Illinois drug lists + CMS guidance
Updated as rules change
Coverage and prior-auth criteria shift often
Verify before you decide
Informational only — not insurance advice

Key facts

  • BCBS of Illinois is an HCSC plan using the same multi-tier drug list as BCBS of Texas — the same PA criteria (T2D diagnosis, A1c 6.5%, metformin trial) apply across both sister plans.

    HCSC / BCBS Illinois Drug List

  • Illinois Medicaid covers Mounjaro for type 2 diabetes but explicitly excludes weight-loss GLP-1s — Zepbound and Wegovy are not covered for obesity under IL Medicaid.

    Illinois Department of Healthcare and Family Services, Medicaid PDL

  • The 2026 Medicare Part D out-of-pocket cap is $2,100. Most Mounjaro users for diabetes who stay on therapy continuously reach this cap within 2–3 months and pay $0 for the rest of the year.

    CMS Medicare Part D Redesign, 2026

Plan types

Medicare vs. commercial coverage

Whether Blue Cross Blue Shield of Illinois covers Mounjaro depends heavily on which kind of plan you hold. They follow completely different rules — here's each one, side by side.

Medicare

Part D & Advantage plans

Conditional

BCBS of Illinois Medicare Advantage and Part D plans cover Mounjaro for type 2 diabetes only — not weight loss — with prior authorization. The 2026 Part D out-of-pocket cap is $2,100; most continuous Mounjaro users for diabetes reach it within 2–3 months and pay $0 for the remainder of the year. The IRA-negotiated Medicare MFN price of $245/month begins mid-2026. Mounjaro is NOT included in the 2026 Medicare GLP-1 Bridge ($50/month), which covers weight-loss-approved products only. The Lilly savings card is not usable by Medicare or Medicaid beneficiaries.

Commercial / Employer

Group & marketplace plans

Conditional

BCBS of Illinois commercial and employer-sponsored plans use the HCSC multi-tier drug list — the same formulary architecture as BCBS Texas. Mounjaro is covered for type 2 diabetes with prior authorization (A1c 6.5% or higher, metformin trial). Specific tier placement should be verified on the BCBSIL drug list. Not covered for off-label weight loss under any plan design. ACA/Individual: diabetes only, PA; weight-loss GLP-1s commonly excluded. Illinois Medicaid: covers Mounjaro for T2D with PA; explicitly excludes weight-loss GLP-1s. Lilly savings card: $25/month with commercial coverage; $499/month without (max $647/month, up to 13 fills, expires 12/31/2026). Not available to Medicare or Medicaid beneficiaries.

Prior authorization

The 5 boxes you must tick to get approved

Commercial plans that will consider Mounjaro require prior authorization. Check off what applies to you to see how close you are — this is a guide, not a guarantee of approval.

Requirements you meet0 / 5

Meet all 5 and you have a documented case for approval. Missing any one is the most common reason requests are denied.

What you'll pay

Your cost, three ways

What Mounjaro actually costs you swings enormously depending on how it's covered. Here's the realistic range.

No coverage

Paying cash

Approximately $1,300–$1,560/month retail (WAC ~$1,080). Lilly savings card: $499/month for commercially insured without coverage (max $647/month, up to 13 fills, expires 12/31/2026). Not available to Medicare or Medicaid beneficiaries.

List price with no coverage — before any manufacturer savings card.

PA approved

With coverage

BCBS Illinois plan-specific brand cost-share on the HCSC multi-tier drug list; verify current tier and cost-share on the BCBSIL drug list. Commercially insured with Mounjaro coverage may pay as little as $25/month via the Lilly savings card. IL Medicaid: nominal copay for covered T2D use. Medicare Part D: 25% coinsurance to the $2,100 OOP cap 2026; MFN $245/month mid-2026.

Typical monthly copay once prior authorization is approved.

Lowest cost

Bridge program

The 2026 Medicare GLP-1 Bridge ($50/month) covers weight-loss-approved products only; Mounjaro is not included.

Reduced copay through the assistance program, where eligible.

All figures are estimates; confirm cost-share on the BCBS Illinois drug lookup tool. The Lilly savings card expires 12/31/2026 and is not available to Medicare, Medicaid, or government-program beneficiaries.

Do it yourself

Check YOUR exact coverage in 3 steps

General answers only get you so far. Here's how to confirm your own plan's decision in a few minutes.

  1. 1

    Verify Mounjaro coverage and tier on the BCBS Illinois drug list

    Visit bcbsil.com and use the drug lookup for your specific plan. BCBS of Illinois uses the HCSC multi-tier drug list — the same platform as BCBS Texas. Confirm that PA is required, look up the current tier and cost-share, and verify the PA criteria. If you have an Illinois Medicaid plan through BCBS IL, note that IL Medicaid explicitly excludes weight-loss GLP-1s.

  2. 2

    Have your prescriber submit a complete prior authorization under the HCSC PA policy

    Your prescriber must document your T2D diagnosis (ICD-10 E11.x), A1c of 6.5% or greater within ~90 days, and prior metformin trial (plus one additional agent where required). Submit through the BCBS Illinois PA portal; allow up to 72 hours for a decision.

  3. 3

    If you want tirzepatide for weight loss, ask about Zepbound — not Mounjaro

    Illinois Medicaid explicitly excludes weight-loss GLP-1s, and BCBS Illinois does not cover Mounjaro for weight loss. The weight-loss tirzepatide is Zepbound, FDA-approved for chronic weight management and OSA. Ask your prescriber and BCBS Illinois about Zepbound coverage on your specific commercial or Medicare plan — it has a separate PA and coverage pathway from Mounjaro.

If it's denied

Options if Blue Cross Blue Shield of Illinois won't cover Mounjaro

A denial isn't the end of the road. These are the paths people commonly explore next — discuss any of them with your prescriber.

Ozempic (semaglutide)

FDA-approved for type 2 diabetes. May be on a preferred tier ahead of Mounjaro as step therapy on the HCSC/BCBS Illinois drug list.

Trulicity (dulaglutide)

FDA-approved for T2D. GLP-1 alternative; often used as a step-therapy agent before Mounjaro approval on HCSC formularies.

Jardiance (empagliflozin)

SGLT2 inhibitor for T2D with cardiovascular benefits. May be required step therapy before GLP-1 approval on BCBS Illinois plans.

BCBS Texas (HCSC sister plan)

BCBS of Texas uses the same HCSC multi-tier drug list. Medicaid diverges: TX Medicaid covers Mounjaro for T2D with PA; IL Medicaid covers T2D but explicitly excludes weight-loss GLP-1s.

Zepbound (tirzepatide) — weight loss only

Same molecule as Mounjaro (tirzepatide) but FDA-approved for chronic weight management and OSA. IL Medicaid explicitly excludes weight-loss GLP-1s — ask about commercial Zepbound coverage separately.

These options are listed for information only — your own clinician decides what is appropriate for you.

Frequently Asked Questions

No. BCBS of Illinois does not cover Mounjaro for weight loss under any line of business. Mounjaro is FDA-approved for type 2 diabetes only; the PA is gated on a T2D diagnosis — off-label weight-loss requests are denied. Illinois Medicaid explicitly excludes weight-loss GLP-1s. For weight loss, the same active ingredient (tirzepatide) is Zepbound — a separate FDA approval with its own coverage pathway.

Health Care Service Corporation (HCSC) operates BCBS plans across Illinois, Texas, Montana, New Mexico, and Oklahoma. BCBS of Illinois and BCBS of Texas share the same HCSC multi-tier drug list and PA architecture — so the Mounjaro PA criteria are essentially identical between the two sister plans. Medicaid diverges: IL Medicaid explicitly excludes weight-loss GLP-1s, while TX Medicaid covers Mounjaro for T2D.

Yes, for type 2 diabetes with prior authorization. Illinois Medicaid covers Mounjaro for T2D at a nominal Medicaid copay. However, IL Medicaid explicitly excludes weight-loss GLP-1s — so Zepbound and Wegovy are not covered for obesity under IL Medicaid. The Lilly savings card is not available to Medicaid beneficiaries.

No. The 2026 Medicare GLP-1 Bridge ($50/month, July 1 – December 31, 2027) covers weight-loss-approved products only — Wegovy, Foundayo, and the Zepbound KwikPen. Mounjaro is excluded because it is FDA-approved for type 2 diabetes, not weight loss. BCBS Illinois Medicare Advantage and Part D plans cover Mounjaro under standard Part D rules for T2D, with PA and the $2,100 annual OOP cap in 2026.

The Curex GLP-1 program

Insurance covers Mounjaro only for diabetes — for weight loss, here's a path that skips insurance

BCBS of Illinois covers Mounjaro for diabetes only, not weight loss — and IL Medicaid explicitly excludes weight-loss GLP-1s. For patients who want tirzepatide access without insurance, compounded tirzepatide from $149/mo (and compounded semaglutide from $49/mo) is available at getcurex.com/cl/glp — no insurance required, no prior authorization. This is compounded tirzepatide and is not the same medication as Mounjaro or Zepbound. Prescription required, subject to provider review.

Compounded semaglutide
from$49/mo
Weekly injection or oral tablet
Compounded tirzepatide
from$149/mo
Injection or oral tablet
  • Medication + free shipping
  • 24/7 provider access
  • Medical intake & prescription review
From $49/moNo insurance requiredNo prior auth
Build your personalized planPrescription required, subject to provider review.

Compounded semaglutide and tirzepatide are not the same medications as Mounjaro and are not branded or FDA-approved products. Compounded medications have not been approved by the FDA and the FDA has not evaluated their safety or efficacy.

This content is for informational purposes only and does not constitute medical, financial, or insurance advice. Coverage rules, prior-authorization criteria, and copay amounts change frequently and vary by plan, formulary tier, and effective date — always verify current benefits directly with Blue Cross Blue Shield of Illinois before making any decision. Consult a licensed healthcare provider and your plan administrator for guidance specific to your situation. Curex offers compounded semaglutide and tirzepatide, which are not the same medications as Mounjaro and are not branded or FDA-approved products; prescription required, subject to provider review. Compounded medications have not been approved by the FDA and the FDA has not evaluated their safety or efficacy.

Weight care with Curex

Insurance covers Mounjaro only for diabetes — for weight loss, here's a path that skips insurance

Build your personalized plan

Compounded medications have not been approved by the FDA and the FDA has not evaluated their safety or efficacy.